Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor

US8183237B2 · kind B2 · utility

Assignees

• Abbott Laboratories · US
• Abbott GmbH & Co. KG · DE

Inventors

• Andreas Haupt · Ludwigshafen, DE
• Frauke Pohlki · Wiesbaden, DE
• Karla Drescher · Ludwigshafen, DE
• Karsten Wicke · Ludwigshafen, DE
• Liliane Unger · Ludwigshafen, DE
• Ana-Lucia Relo · Ludwigshafen, DE
• Anton Bespalov · Ludwigshafen, DE
• Barbara Vogg · Ludwigshafen, DE
• Gisela Backfisch · Dossenheim, DE
• Juergen Delzer · Ludwigshafen, DE
• Min Zhang · 安丰镇, CN

Key dates

• Filing date: Apr 29, 2010
• Grant date: May 22, 2012
• Expiry date: Apr 29, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D405/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to novel benzenesulfonanilide compounds of the formulae I and I′ and physiologically tolerated acid addition salts and the N-oxides thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT6 receptor.